Publication:
International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV

dc.contributor.authorSinger, Susanne (8044967900)
dc.contributor.authorAmdal, Cecilie Delphin (35482981700)
dc.contributor.authorHammerlid, Eva (6601966076)
dc.contributor.authorTomaszewska, Iwona M. (55702103400)
dc.contributor.authorCastro Silva, Joaquim (55509889400)
dc.contributor.authorMehanna, Hisham (11839081200)
dc.contributor.authorSantos, Marcos (56276517700)
dc.contributor.authorInhestern, Johanna (55243353800)
dc.contributor.authorBrannan, Christine (57191847313)
dc.contributor.authorYarom, Noam (8317667000)
dc.contributor.authorFullerton, Amy (18634351100)
dc.contributor.authorPinto, Monica (55338042000)
dc.contributor.authorArraras, Juan I. (6701753532)
dc.contributor.authorKiyota, Naomi (23492603200)
dc.contributor.authorBonomo, Pierluigi (54911583000)
dc.contributor.authorSherman, Allen C. (7201763995)
dc.contributor.authorBaumann, Ingo (7006255873)
dc.contributor.authorGalalae, Razvan (6701597227)
dc.contributor.authorFernandez Gonzalez, Loreto (56625967900)
dc.contributor.authorNicolatou-Galitis, Ourania (6701317806)
dc.date.accessioned2025-06-12T15:12:55Z
dc.date.available2025-06-12T15:12:55Z
dc.date.issued2019
dc.description.abstractBackground: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test–retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life. © 2019 Wiley Periodicals, Inc.
dc.identifier.urihttps://doi.org/10.1002/hed.25609
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85059916248&doi=10.1002%2fhed.25609&partnerID=40&md5=537d9198015ccfc47499f3362d51ddbc
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/5581
dc.subjectchemoradiation
dc.subjecthead and neck cancer
dc.subjectmultimodal therapies
dc.subjectquality of life
dc.subjectvalidation
dc.titleInternational validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV
dspace.entity.typePublication

Files